Cargando…
Clinical implications of trials investigating drug‐drug interactions between cannabidiol and enzyme inducers or inhibitors or common antiseizure drugs
Highly purified cannabidiol (CBD) has demonstrated efficacy with an acceptable safety profile in patients with Lennox‐Gastaut syndrome or Dravet syndrome in randomized, double‐blind, add‐on, controlled phase 3 trials. It is important to consider the possibility of drug‐drug interactions (DDIs). Here...
Autores principales: | Patsalos, Philip N., Szaflarski, Jerzy P., Gidal, Barry, VanLandingham, Kevan, Critchley, David, Morrison, Gilmour |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693203/ https://www.ncbi.nlm.nih.gov/pubmed/32918835 http://dx.doi.org/10.1111/epi.16674 |
Ejemplares similares
-
A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam
por: VanLandingham, Kevan E., et al.
Publicado: (2020) -
A Phase II Randomized Trial to Explore the Potential for Pharmacokinetic Drug–Drug Interactions with Stiripentol or Valproate when Combined with Cannabidiol in Patients with Epilepsy
por: Ben-Menachem, Elinor, et al.
Publicado: (2020) -
Is cannabidiol a drug acting on unconventional targets to control drug‐resistant epilepsy?
por: Rocha, Luisa, et al.
Publicado: (2020) -
Neuropharmacology of Antiseizure Drugs
por: Hakami, Tahir
Publicado: (2021) -
Efficacy and tolerability of antiseizure drugs
por: Hakami, Tahir
Publicado: (2021)